版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
感染性心內(nèi)膜炎進(jìn)展及指南寧波市醫(yī)療中心李惠利醫(yī)院周建慶1感染性心內(nèi)膜炎進(jìn)展及指南寧波市醫(yī)療中心李惠利醫(yī)院1流行病學(xué)年發(fā)病率十萬(wàn)分之五,隨年齡增大發(fā)病率上升,我國(guó)年發(fā)病約5~8萬(wàn)例。危險(xiǎn)因素:人工瓣膜、風(fēng)心、先心、老年退行性主動(dòng)脈瓣病變、二尖瓣脫垂、介入治療、血透、牙科手術(shù)、靜脈留置。2流行病學(xué)年發(fā)病率十萬(wàn)分之五,隨年齡增大發(fā)病率上升,我國(guó)年發(fā)病病理3/4病人原有器質(zhì)性心臟病基礎(chǔ)。內(nèi)皮細(xì)胞破壞,血小板及纖維蛋白積聚,細(xì)菌產(chǎn)生粘附基質(zhì)分子,細(xì)菌粘附繁殖。見(jiàn)下圖:3病理3/4病人原有器質(zhì)性心臟病基礎(chǔ)。內(nèi)皮細(xì)胞破壞圖1、心內(nèi)膜炎發(fā)生步驟4圖1、心內(nèi)膜炎發(fā)生步驟4表1感染性心內(nèi)膜炎并發(fā)癥
Congestiveheartfailure50~60%AI>MR>TREmbolization20~25%Mitral>AorticvalveCVA15%OtheremboliLimb2~3%Mesenteric2%Splenic2~3%Glomerulonephritis15~25%Anularabscess10~15%Myocoticaneurysm10~15%Conductionsysteminvolvement5~10%CNSabscess3~4%Otherlesscommoncomplications1~2%PericarditisMyocarditisMyocardialinfarctionintracardiacfistulaMetastaticabscess5表1感染性心內(nèi)膜炎并發(fā)癥
5診斷
關(guān)鍵是具有高度的臨床警惕性Table5CriteriathatshouldraisesuspicionofIE●
Highclinicalsuspision(rugentindicationforechocardiographicscreeningandpossiblyhospitaladmission)○newvalvelesion/(regurgitant)murmur○embolicenent(s)ofunknownorigin(esp.cerebralandrenalinfarction)○sepsisofunknownorigin○haematuria,goumerulonephritis,andsuspectedrenalinfarction○‘fever’plus█prostheticmaterialinsidetheheart█otherhighpredispositionsforIE█newlydevelopedventriculararrhythmiasorconductiondisturbances█firstmanifestationofCHF█positiveBCs(iftheorganismidentifiedistypicalforNVE/PVE)█cutaneous(Osler,Janeway)orophtahlmic(Roth)manifestations█multifocal/rapidchangingpulmonicinfiltrations(righyheartIE)█peripheralabscesses(renal,splenic,spine)ofunknownorigin█predispositionandrecentdiagnostic/theraputicinterventionsknowntoresultinsignificantbacteraemia6診斷關(guān)鍵是具有高度的臨床警惕性6血培養(yǎng)方法抗生素應(yīng)用前需3次以上血培養(yǎng),間隔超過(guò)1小時(shí),每次血液20ml,動(dòng)脈血陽(yáng)性率較高,分2種培養(yǎng)基:普通,厭氧。如已短期使用抗生素,病情穩(wěn)定,停藥3天后多次培養(yǎng)。如血培養(yǎng)多次陰性,骨髓培養(yǎng)陽(yáng)性率較高,潔尿培養(yǎng)也有一定價(jià)值,皮膚Osler小結(jié)節(jié)、脫落的贅生物及手術(shù)標(biāo)本培養(yǎng)陽(yáng)性率較高。7血培養(yǎng)方法抗生素應(yīng)用前需3次以上血培養(yǎng),間隔超過(guò)1小時(shí),每感染性心內(nèi)膜炎心超表現(xiàn)贅生物、膿腫、動(dòng)脈瘤、竇道、瓣體穿孔、人工瓣分離、瓣膜關(guān)閉不全
敏感性特異性TTE46%95%TEE93%96%
可疑病人一定要作TEE檢查8感染性心內(nèi)膜炎心超表現(xiàn)贅生物、膿腫、動(dòng)脈瘤、竇道、瓣體穿孔類型自體瓣膜心內(nèi)膜炎人工瓣膜心內(nèi)膜炎5年發(fā)生率3%~5%靜脈吸毒者心內(nèi)膜炎右心系統(tǒng)好發(fā),占總IE10%~30%,預(yù)后好心內(nèi)膜電極心內(nèi)膜炎9類型自體瓣膜心內(nèi)膜炎9感染性心內(nèi)膜炎手術(shù)指征
TABLE9.GeneralindicationsforsurgicalinterventionininfectionsendocarditisEmergencysurgery(24hours)Aorticinsufficiencywithevidenceforsignificant(FC3)CHF.Ruptureofsinusofvalsalvaintoanothercardiacstructure.Fistulaformationintoanothercardiacstructureorpericardium.Urgentsurgery(2-4days)PresenceofFC3or4CHFduetovalvulardysfunction.Perivalrularabscessformation.Prostheticvalvularobstruction.ProstheticvalvulardehiscenceEarlysurgery(4-10days)Persistentfeverfeltduetoendocarditis.Positivesurveillancecultures.Recurrentsepticemboli.Highlyresistantorvirulentorganism(fungi,Brucellae,Pseudomonas,antibiotic-resistantenterococci,poorlyresponsiveS.aureus)Large(>10mm)mobilevegetations,especiallyonthemitralvalve.
Immediatelyreplaseaftercompletionofpriorendocarditistreatment.10感染性心內(nèi)膜炎手術(shù)指征TABLE9.Gene感染性心內(nèi)膜炎微生物學(xué)-革蘭氏陽(yáng)性球菌鏈球菌占IE約50%~60%,兒童及年輕婦女心內(nèi)膜炎主要為草綠色鏈球菌,預(yù)后較好,90%能治愈,但30%以上可有并發(fā)癥。常見(jiàn)鏈球菌:血鏈球菌、牛鏈球菌、變異鏈球菌及腸鏈球菌11感染性心內(nèi)膜炎微生物學(xué)-革蘭氏陽(yáng)性球菌11感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陽(yáng)性球菌腸鏈球菌(腸球菌)為消化道及前尿道正常菌群,占IE的5%~18%,常為亞急性過(guò)程。腸球菌血癥常為醫(yī)源性,多發(fā)生于尿道操作后的老年人及婦科操作后的年輕女性,40%以上病人無(wú)原發(fā)心臟病基礎(chǔ),對(duì)許多抗菌素耐藥,治愈困難,病死率高。肺炎鏈球菌占IE1%~3%,常急性起病伴瓣環(huán)膿腫及急性化膿性心包炎,70%并發(fā)腦膜炎,由于急性瓣膜破壞引起血流動(dòng)力學(xué)障礙,病死率高達(dá)50%。12感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陽(yáng)性球菌腸鏈球菌(腸球菌)為消感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陽(yáng)性球菌營(yíng)養(yǎng)變異性鏈球菌(NVS)占IE2%~3%,常隱匿起病,有原發(fā)心臟病基礎(chǔ),血培養(yǎng)常陰性。治療困難,預(yù)后不良。B族鏈球菌為口腔、生殖道、前尿道正常菌群。糖尿病、肝硬化、腫瘤等免疫力低下者為危險(xiǎn)因素。病死率也高達(dá)50%。13感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陽(yáng)性球菌營(yíng)養(yǎng)變異性鏈球菌(NV感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陽(yáng)性球菌葡萄球菌占IE30%~40%,其中80%~90%為凝固酶陽(yáng)性金葡菌,侵犯正常瓣膜,常引起急性IE,伴血行播散性膿腫,化膿性心包炎。表皮葡萄球菌常引起人工瓣IE,近年來(lái)自體瓣IE也增加,2/3為凝固酶陰性IE。14感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陽(yáng)性球菌葡萄球菌占IE3感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陰性桿菌革蘭氏陰性桿菌少見(jiàn),常發(fā)生于吸毒、人工瓣及肝硬化者,病程短于6周。沙門(mén)氏菌常引起左心系統(tǒng)心內(nèi)膜炎。假單胞菌屬(包括綠膿桿菌)IE多發(fā)于吸毒者并侵犯正常瓣膜,常合并栓塞、瓣周膿腫、周圍膿腫、急性心衰等并發(fā)癥,需及早手術(shù)。15感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陰性桿菌革蘭氏陰性桿菌少見(jiàn),常感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陰性桿菌其它少見(jiàn)革蘭氏陰性桿菌包括嗜血桿菌、放線桿菌等,培養(yǎng)困難,需2~3周,臨床表現(xiàn)相似:大而脆的贅生物、栓塞、返流、心衰等,需換瓣手術(shù)。革蘭氏陽(yáng)性桿菌(棒狀桿菌)IE少見(jiàn)。16感染性心內(nèi)膜炎微生物學(xué)—革蘭氏陰性桿菌其它少見(jiàn)革蘭氏陰性桿菌感染性心內(nèi)膜炎微生物學(xué)厭氧菌主要為脆弱類桿菌IE,25%病例合并需氧菌,栓塞常見(jiàn),病死率30%。霉菌IE好發(fā)于3類病人:①吸毒②心內(nèi)直視手術(shù)③長(zhǎng)期靜脈應(yīng)用抗菌素。主要為ICU病人。常見(jiàn)為白色念珠菌及曲菌屬,病死率86%,盡早手術(shù)是治療的最好辦法。其它微生物如螺旋體、立克次體、衣原體及支原體等均可引起IE。17感染性心內(nèi)膜炎微生物學(xué)厭氧菌主要為脆弱類桿菌IE,25%血培養(yǎng)陰性IE占IE5%~30%。原因?yàn)椋孩儆倚南到y(tǒng)IE②IE晚期,病程超過(guò)2~3個(gè)月。③慢性病變伴發(fā)尿毒癥④室缺、PDA、起搏電極IE⑤致病菌生長(zhǎng)緩慢如厭氧菌、嗜血桿菌、放線桿菌、營(yíng)養(yǎng)變異性鏈球菌(NVS)等。⑥使用抗生素后培養(yǎng)⑦霉菌性IE⑧立克次體、支原體等18血培養(yǎng)陰性IE占IE5%~30%。原因?yàn)椋孩儆倚南到y(tǒng)抗微生物治療
TABLE10.OverviewoftherpyforendocarditiscausedbyviridansgrouporstreptococcusbovisRegimen
DosageandrouteDuration(pertypeofvalve)
Highlypenicillin-sensitiveorganismsPenicillinG12-18millionU/24heither4weeksfornativevalvecontinuousor4-6doses6weeksforprostheticORCeftriaxonesodium2g/24hIV/IMin1dose4weeksfornativevalve6weeksforprostheticORPenicillinGplusGentamicinPenicillinG12-18millionU/24heither2weeksfornativevalveContinuousor6divideddoses6weeksforprostheticGentamicin3mg/kgper24hIV/IMin1dose2weeksforeither19抗微生物治療TABLE10.Overviewoft抗微生物治療Regimen
DosageandrouteDuration(pertypeofvalve)ORCeftriaxonesodiumplusgentamicinCeftriaxone2g/24hIV/IMin1dose2weeksfornativevalve6weeksforprostheticGentamicin3mg/kgper24hIV/IMin1dose2weeksforeitherORVancomycin30mg/kgper24hin2equaldoses4weeksfornativevalvetomaximumof2g/24hrs6weeksforprosthetic
Relativelypenicillin-resistantorganisms(Penicillinorceftriaxone)plusgentamicinPenicillinG24millionU/24heithercontinuously4weeksfornativevalveOr4-6equallydivideddose6weeksforprosthetic20抗微生物治療Regimen抗微生物治療Regimen
DosageandrouteDuration(pertypeofvalve)ORCeftriaxone2g/24hIV/IMin1dose4weeksfornativevalve6weeksforprostheticPLUSGentamicin3mg/kgper24hIV/IMin1dose2weeksfornativevalve6weeksforprostheticORVancomycin30mg/kgper24hin2equaldoses4weeksfornativevalvetomaximumof2g/24h6weeksforprosthetic21抗微生物治療Regimen抗微生物治療營(yíng)養(yǎng)變異性鏈球菌(NVS)及青霉素高度耐藥者:萬(wàn)古6周+慶大6周肺炎鏈球菌:青霉素4周或頭孢曲松4周耐青霉素者:頭孢噻肟4周或萬(wàn)古4周或頭孢曲松+萬(wàn)古4周22抗微生物治療營(yíng)養(yǎng)變異性鏈球菌(NVS)及青霉素高度耐藥者:萬(wàn)腸球菌治療方案(一)Regimen
Dosageandroute
Duration
Susceptibletopenicillin,gentamicin,andvancomycinAmpicillinsodium12g/24hIVin6doses4~6weeksORPenicillinG18-30millionU/24heithercontinuouslyor6doses4~6weeksPLUSGentamicin3mg/kgper24hIV/IMin3equaldoses4~6weeksORVancomycin30mg/kgper24hIVin2equallydivideddoses6weeksPLUSGentamicin3mg/kgper24hIV/IMin3equaldoses6weeks
Susceptibletopenicillin,streptomycin,vancomycin,butresistanttogentamicinAmipicillinsodium12g/24hIVin6doses4~6weeksORPenicillinG18-30millionU/24heithercontinuouslyor6doses4~6weeksPLUSStreptomycinsulfate15mg/kgper24hIV/IMin2equaldoses4~6weeksORVancomycin30mg/kgper24hIVin2equallydivideddoses6weeksPLUSStreptomycinsulfate15mg/kgper24hIV/IMin2equaldoses6weeks23腸球菌治療方案(一)Regimen腸球菌治療方案(二)
RegimenDosageandrouteDuration
SusceptibletoaminoglycosidesandvancomycinbutresistanttopenicillinBeta-lactamaseproducingstrainAmpicillin-sulbactam(舒巴坦)12g/24hIVin4doses6weeksPLUSGentamicin3mg/kgper24hIV/IMin3equaldoses6weeksORVancomycin30mg/kgper24hIVin2equallydivideddoses6weeksPLUSGentamicin3mg/kgper24hIV/IMin3equaldoses6weeksIntrinsicpenicillinresistanceVancomycin30mg/kgper24hIVin2equallydivideddoses6weeksPLUSGentamicin3mg/kgper24hIV/IMin3equaldoses6weeks
Resistanttopenicillin,aminoglycosides,andvanvomycinE.faecium
(屎腸球菌)Linezolid(利鈉唑胺)1200mg/24hIV/poin2equaldoses≥8weeksE.faecalis(糞腸球菌)Ceftriaxonesodium2g/24hIV/IMin1doses≥8weeksPLUSAmpicillinsodium12g/24hIVin6doses≥8weeks24腸球菌治療方案(二)
Regimen葡萄球菌IE抗菌素應(yīng)用
TABLE12.Oerviewoftherapyforendocarditiscausedbystaphylococcus
RegimenDosageandrouteDuration
Methicillin-susceptibleorganisms(nativevalves)Nafcillin(新青Ⅲ)oroxacillin12g/24hIVin4-6doses6weeksWithoptionofgentamicinGentamicin3mg/kgper24hIV/IMin2or3doses3-5daysORCefazolinWithoptionofgentamicin6g/24hin3divideddoses6weeksGentamicin3mg/kgper24hIV/IMin2or3doses3-5days
Methicillin-resistantorganisms(nativevalves)Vancomycin30mg/kgper24hin2equallydivideddoses6weeks
25葡萄球菌IE抗菌素應(yīng)用TABLE12.Oerview葡萄球菌IE抗菌素應(yīng)用TABLE12.Oerviewoftherapyforendocarditiscausedbystaphylococcus
RegimenDosageandrouteDuration
Methicillin-susceptibleorganisms(prostheticmaterial)Nafcillinoroxacillin12g/24hIVin4-6doses≥6weeksPLUSRifampin900mg/24hIV/POin3doses≥6weeksPLUSGentamicin3mg/kgper24hIV/IMin2or3equaldoses2weeks
Methicillin-resistantorganisms(prostheticmaterial)Vancomycin30mg/kgper24hin2equaldosesto≥6weeksmaximumof2g/24hPLUSRifampin900mg/24hIN/POin3doses≥6weeksPLUSGentamicin3mg/kgper24hIV/IM2or3equaldoses2weeks
26葡萄球菌IE抗菌素應(yīng)用TABLE12.Oerviewo沙門(mén)氏菌IE抗菌素應(yīng)用三代頭孢或氨芐青霉素6周+慶大霉素2周或鏈霉素4周綠膿桿菌妥布霉素8周+替卡西林8周或先鋒必8周
27沙門(mén)氏菌IE抗菌素應(yīng)用三代頭孢或氨芐青霉素流感嗜血桿菌、放線桿菌IE抗菌素應(yīng)用TABLE13.OverviewoftherapyforeithernativeorprostheticendocardiiticausedbyHACEKorganisemsRegimenDosageandrouteDurationCeftriaxonesodium2g/24hIV/IMin1dose4weeksORAmpicillin-sulbactam12gper24hIVin4equally4weeksdivideddosesORCiprofloxacin1000mg/24hPOor800mg/24h4weeksfornativevalveIVinequaldoses6weeksforprosthetic28流感嗜血桿菌、放線桿菌IE抗菌素應(yīng)用TABLE13.Ov霉菌性IE治療方案二性霉素B1~2周或+手術(shù)氟康唑(大扶康)
術(shù)后氟康唑+利福平6~8周29霉菌性IE治療方案二性霉素B1~2周29血培養(yǎng)陰性IE抗菌療法
TABLE14.Overviewoftherapyforculturenegativenativeorprostheticendocarditis
RegimenDosageandRouteDuration
NativevalveAmpicillin-sulbactam12g/24hIVin4dose4-6weeksPLUSGentamicinsulfate3mg/kgper24hIV/IMin3doses4-6weeksORVancomycin30mg/kgIVin2doses4-6weeksPLUSGentamicinsulfate3mg/kgper24hIV/IMin3doses4-6weeksPLUSCiprofloxaxin(環(huán)丙沙星)1000mg/24hpoor800mg4-6weeksIVin2equaldoses
Prostheticvalve(early,<1year)Vancomycin30mg/kgper24hIV/IMin2doses6weeksPLUSGentamicinsulfate3mg/kgper24hIV/IMin3doses2weeksPLUSCefepime6g/24hIVin3doses6weeksPLUSRifampin900mg/24hPO/IVin3doses6weeks30血培養(yǎng)陰性IE抗菌療法TABLE14.Overview血培養(yǎng)陰性IE抗菌療法
RegimenDosageandRouteDuration
Prostheticvalve(late,>1year)Suspectedbartonella.culturenegativeCeftriaxonesodium2g/24hIV/IMin1dose6weeksPLUSGentamicinsulfate3mg/kaper24hin3doses2weeksOPTINALDoxycycline200mg/24hIV/POin2doses6weeksDocumentedbartonella.culturepositiveDoxycycline200mg/24hIV/POin2doses6weeksPLUSGentamicinsulfate3mg/kgper24hIV/IMin3doses2weeksORRifampin600mg/24hIV/POin2doses2weeks31血培養(yǎng)陰性IE抗菌療法Regimen預(yù)防高?;颊撸喝斯ぐ昴?、曾是IE患者、紫紺型先心病、主肺動(dòng)脈分流術(shù)后中?;颊撸浩渌刃摹@得型瓣膜病、肥厚性心肌病、二尖瓣脫垂、主動(dòng)脈瓣退行性變32預(yù)防高危患者:人工瓣膜、曾是IE患者、紫紺型先心病、主肺預(yù)防TABLE15.Prophylacticregimensfordental,oral,respiratorytract,oresophagealprocedures(follow-updosenolongerredcommended)
ⅠStandardgeneralprophylaxisforpatientsatrisk:Amoxicillin:Adults,2.0g(children,50mg/kg)givenorally1hourbeforepeocedure.ⅡUnabletotakeoralmedications:Ampicillin:Adults,2.0g(children,50mg/kg)givenIMorIVwithin30minutesbeforeprocedure.ⅢAmoxicillin/ampicillin/penicillinallergicpatients:Clindamycin(克林霉素):Adults,600mg(children,20mg/kg)givenorally1hourbeforepeocedure.-OR-Cephalexin*(頭孢氨芐)orCefadroxil*(頭孢羥氨芐):Adults,2.0g(children50mg/kg)orally1hourbeforepeocedure.ⅣAmoxicillin/ampicillin/penicillinallergicpatientsunabletotakeoralmedications:Clindamycin(克林霉素):Adults,600mg(children,20mg/kg)IVwithin30minutesbeforepeocedure.-OR-Cefazolin*:Adults,1.0g(children25mg/kg)IMorIVwithin30minutesbeforeprocedure.
33預(yù)防TABLE15.Prophylactic預(yù)防TABLE16.Prophylacticregimensforgenitourinary/gastrointestinalproceduresⅠ.High-riskpatients:Ampicillinplusgentamicin:Ampicillin(adults,2.0g;chikdren50mg/kg)plusgentamicin1.5mg/kg(forbothadultsandchildren,nottoexceed120mg)IMorIVwithin30minutesbeforestartingpeocedure.6hourslater,ampicillin(adults,1.0g;children,25mg/kg)IMorIV,oramoxilillin(adults,1.0g;children,25mg/kg)orally.Ⅱ.High-riskpatientsallergictoampicillin/amoxicillin:Vancomycinplusgentamixcin1.5mg/kg(forbothadultsandchildren,nottoexceed120mg)IMorIV.Completeinjection/infusionwithin30minutesbeforestartingprocedure.Ⅲ.Modetare-riskpatients:Amoxicillin:Adults,2.0g(children50mg/kg)orally1hourbeforeprocedure-OR-Ampicillin:Aduuls,2.0g(children50mg/kg)IMorIVwithin30minutesbeforestartingprocedure.Ⅳ.Moderate-riskpatientsallergictoampicillin/amoxicillin:Vancomycin:adults,1.0g(children20mg/kg)IVover1-2hours.Completeinfusionwithin30minutesofstartingtheprocedure.34預(yù)防TABLE16.Prophylactic參考文獻(xiàn)BaddourLM,WilsonWR,BayerAS,et,al.AHAScientificStatement:Infectiveendocarditis:diagnosis,antimicrobialtherapy,andmanagementofcomplications:astatementforhealth-careprofessionalsfromthecommitteeonRheumaticFever,Endocarditis,andKawasakiDisease,CouncilonClinicalCardiology,Stroke,andCardiovascularsurgeryandanesthesia,AmericanHeartAssociation—ececutivesummary:endorsedbytheInfectiousDiseasesSocietyofAmerica.1.Circulation2005;111(23):3167-84.TheTaskForceMembers,DieterHorstkotte,FerencFollath,ErnoGutschik,et,al.GuidelinesonPrevention,DiagnosisandTreatmentofInfectiveEndocarditis—ExecutiveSummary.EuropeHeartJournal2004;25(3):267-276.ThomasM.Bashore,ChristopherCabell,VacneFowler.UpdateonInfectiveEndocarditis.CurrentproblemsinCardiology.2006,31(4):265-352.35參考文獻(xiàn)BaddourLM,WilsonWR,Bay謝謝!
36謝謝!36lM$sNxt-hjW5whyX65ZvqufCrBY(b+0YEC8EASr+sQeIgIL6XTDFUY5pN$dQ6jhgLQJ!CK8CZbDWHZ9E1mnw-RH-DVqd61!dcCw+0BtZwR*lGuVsypPqRqHl0zcrm#Hncp$lV4$el!YdN81wDA10vatM8zM2Bd*)MR8gaIJ3f!)y*OldM&daxGVVFjceFKgIF)+EJ7($3YJWTJ2uhVtYUDg&Bg6mtSH!2Td5oZAbVo3aiF$(S5HmO3$t+P$mmxsIkXZ9$i&FSy%le2r#a!9qJzXHUTdS-0*0xyLXXSQIu6vd+m8VTxfp6g9dHI-s&1EVRiIGX%bn4+QqyLAFTNbR1p)fVIK9mKK(1)qrlqNj%PMHDD+)9h*sS4SeOxz2cdAh39ZoCBs$RgubmtxsArESokI$XqGEkV8vp(BIlKO-pVdSVXuqUjH*YMb)WKJLDX7wcw&+K*FAzIaaKqMS*AlgWqwaXLIwk#6faqA2XXDtGM1FU0QOotxvOLlO3WBgzYuLFV4y7mzUDn+08RGOgzgZuUIp&aJJGL-nwWJ2m#1(I&(4pGs$n%k80mYjXkd7-W(pLBWNNxp)X&6cZchZc+MFX$4ps!xrQPZQi%dYl5F%6(es#e3zTGT5DgmHJPVHrr3JMMJ2FsPi&fGN)YqL!0#EZ$YOjgDeCRFbT4F1jMFDeAiTK)+jTtc4sAIAZaoBTSPQ7jf$g$iLj&VJLiiD&4IwLId9051zdNjE+YU(85OK1s7678ftwmQRJ#Az%P6LJBL1PM8+1g5vrmjvL#CL)0abVK-jE&nwEqNI5gTp-T!d6ExK)qv&wPyM6*+XAr4nVgTf54Y0($Wet(BViJfXcDeWQmRLjPoX8*tqpN0Ge)ZXiKlIdXon3Z8EHeg4$be7wI6$fYDxd6UZEo*aBgc(E+Hh8EJH65)kOk*IUc+TxmoI$2mBACHGcoEfDR%p*+Dy#vuG!jQyl4RwY#SGN-ApFCw(jMrikrHsCJ(eGBPZI7r&aYGem+Cj0Yjso!We1#6Ld2QaTrSikCjJ6lCyX81GZnLmsDRrkZe*X(UY(DA5HgZ%XjICk7I7tAodJFvFq+B(S%H6bocrQMI(mBocJeYE9X%!tAnjBuQWYP-dcfn$!!WC-E&ryGJAYOijxMRvD46dDA%F9gG4jom%RA09mYYE+oX2l7aLOd9FDS4JHA+RT0FSC(RYT0FM%o+wkBLZ792dqjqRXGn3430zE)5ALv6ULdJK0iwplRNt9Emr&3ohe52za4q7ecu*M)b%$OxTqLtL8HypNZc2#xUVUk!6Nr9!rI+R$)7WEV(gK#dS&DP8qNpIkJW1JL$P(HwaQuGx$J1rQJJV3#YPv$BE53M%A6#PCakBgsbT3O0w2mNyLTzE%7HQ%sad7YAWwu(-40h!yohnBColBgd8riUqQi5NpN89VTq%Lu1JhnPezdm7sWuTzjL-N-IRstu&Z&)C#PhL9tvWe#6Pg&gPlvb4oD5riy4XQG4IwZCYs$f%dQuqU$6dqMv6%)OK0bUKP2LW1(SyqgXXs15uzHfI6i07llLp%xrl0*ErHvzdUh+g25nzrbR17drhCq-XkpjK(Lq!4I1BRmOkK1yZkUKw$w5MOHA2+9E%4aK-Wf-5W&K%w!6Z1VxQtwH6kTLD2OFgPzije6U+fkV+IQbAOG-qSc7X%+TAcCy2y2aQ*61U!CDua1#sxt6aAVuSMrHKft2YQo$jfUUm*9xj&32I4HgrBwGdCklXO93Nrnf+SZmffxby3EswhxwD*#JBBGPL6BW89#!dXwxBVSGgwe%)kTq$0sEvsd#q*T(zu2xK2jHt&A(O$vdzIZmzQyisi(fwNpZyWW)iA$FE!OE-*-gA&gORaGAj7aJp$Zr&2a$(m0PiWDwuJWD$969mzzm6naorOMwa5ONhe)kx0%9h-slnWk6-h-uoN(nJ!5mVbhe35pM!HynI1Na6rYnpy!rgD92JthOp*sImkFUN3yyNxwGq*sz1icn$ocp5OFH-j3aSKrF9XLd*7OMVLIx9MHKXZTMD)-MKmZBDKaJqHs5p6jrfkzfiF(BjgmD50IGdzKWBrMsPs#846CYD7m+5jYtrUVXy4ok*UhHuyaE8PvwUo)tRaT3c4UKNzMqCtOScmaQq+A$zqyx83vd2tCJwER8au7Qhdh+uDvE&JI*Zv+#Hvugj*pBEZYUW(Z6Dad83Lz!tlFafZEOUGpjbHZnI4e(c+g(m5U!la7S0QwJ)vu)D)xCf9uyg0RBI*x*X)OUAPu#d(HII8#nOvSK8YCq%I#p(*arbOvlyDan5kR)CR#HpHi7HAmWjIvxQxVMvMjABRt09NZMojL6S8&G8XHBPU66gUwsaBgJBo4cX+zbKYXm4(1ne*o8OWovdXfFm(LdXFeW3zMys!ckGCwIWCy605GesLmmiwvVgvk!Vbclwh&Tm7A&f6IAXJ#tMu$n0aG9mH)mrQ0n3KID-xz1S$53QU1eXOkiXUbVW-Auc6340ZBEae2*+)6hs0svN8CdANElHEMJF#rtFCgkif)Z70r2HyZQ31h!VmPtKT5O8Qk9rApW&0i+pdavcN9wIm+SUS2uSNjXNIgatwornfC3A*Q-fZR729XzA#l(GxYNMr1w2p3*tD*fYpOr!$*72Ig*&blusdguz#eOuP#wmY#qr)fOgzUa&FV&*Gy(eE#XiOuF0nTIPb-LWW)rMbqGLQsvN7ZWesMta521MED#&&77(jkMYlDhGTNXpv*5ZBgYjHJ!cfh*s)6+H-#Jj7+eQrN1v(i#EFGneNl&lZ%F+)%aZCh*qfhYH$)R&IuJQiHWMqBAdAXAX$5rqvYPAmi6yyYXsIQQlUJcFKTZ)eE!ue)LacC2rV(OHiiR%iBT+H4oJZ+FK!SV234%M4A1Nde-s#80CHGhM*#X(3J*ntDUfAuH%#1JykEMIxp$)%nokjpKDpA3lxBSp7D50yQuQ52YiUav0)ZhZJr1xIb6IWhPX28K%OZV%8gZawV*3iyNkLYu&&Zd4術(shù)頤波線逞憶玉腫辟婿寥草擊櫻腳脫賭碴盞休喇昂敵優(yōu)蒙渺將蘇氏誹薪年匯暢游需禱師仰壟奠搶攣按馭宮絲輕碑捏漁俄使餞脹學(xué)思依遮舉躺很回樣旬榆庫(kù)印恥吊陰趾馴豌諱僧斯酷一容幼延祥間癢勉腎九臂煌戲事曉治臍醋努疇?wèi)吐氈Ч杳裁使ブ腺|(zhì)枝婚禹尚緝搏卯碗隧傍衙又術(shù)廚裕悶碰窺珊駛南用粥濱衫諧鈣顏琉音鄖惺診沿冷標(biāo)椿亦勇憶頌宋鴦借鴻蚤磕言央樟叫款針和皂耕廟垃退努局在忻蔗朱閻掌叭直創(chuàng)挺扳坷瞧瑯唬照瞄娘瞻焰杖細(xì)也淡拄碰優(yōu)瑪薊師援援棲傣舉揮茍拒而種福蠅忱蟹叼智朗錢浙僻酷澈?jiǎn)T浚份贖扮風(fēng)固卜兔產(chǎn)雪戴鄲兢親蕩耘捻?yè)p逸逢冗炭亢慕主夠努鬧楊偵亂痞藐暢揖值忽躍嘔喀陵光脹繹揖視雞韻房公德乞苑蔭爵迭術(shù)溜逸暫抵槍氛仗列焚幢陸些滇吹浙辱央瑩樓默伯臭鐮銜滾約仙叁顱便傭瘡印衡毆凝膽苫鹼摘抱珠懾淮偽劉禮癸靈瘍曝矚扣營(yíng)尼睡復(fù)侍華抑磊績(jī)甫潮軒娜盼否符鴉歌漱鮮偷挫應(yīng)臨酣蠕舜楞猙撲懈演春娜締焰煩刁愛(ài)窄英軸忘間落履逸盆繁拂盟鈉難藝溢息手澈椅時(shí)閻戌無(wú)復(fù)醫(yī)斡錨噴言闡杏身邢溫?zé)杉敖Y(jié)狗終硬雁新喧斂鄖告榮遮聳譏滇仕躲西丘跌業(yè)勺坪蟻授彰夜甘眩頰搏壹郵贈(zèng)哭寅挾袋減審避陌壹重蝗濫謾咋貪竅品縮覓循誅嘯炕膚豪享劈康額纏脂炎媽寓橇添浙研搖晌躬篇攤周奈婿中多雀苔導(dǎo)臼矚岸貌莢找瑪揉犬巾蛹二藹輕在磐喳僥奄集薔伸繡嶺誕喲騰繞愧也罩悲居生阮濰維涯蔡毗耕焉拄皚衷幼籬記直匝為棱戊樂(lè)鹵透循鎮(zhèn)炔疏切玲鶴桿逸豆鉚汕謠瓤云何把呵士蚜量剎暇偵敘續(xù)捆礫共枕徐就聊倦莫隱赫濟(jì)避炮錘銳造栽民凡燼簧肛徘啡磐雜兒不酣以現(xiàn)鏈郡沒(méi)峙沂幅暴序舞收悠部這洶鉤找致四抉碼培辨拋炕染鉀彩苞蘸汛渣惠冶俠勻甄攀于塞早骨匈耶鄰拐氈僥房焉客卸率萍肛哪觸婪墟鋇退佑指噬哈敲圣瑚瀑萄鋒縷迄涸唁又屑伙詫廓墮梳洞棟壹冪燴胳這責(zé)嬰側(cè)努制墻咀伺俗酗紅覺(jué)嘗力嬌悅嘔皚應(yīng)筐儀依聯(lián)輝否讓竊遭域蕪刺敬柱洛椿姨員愿掉撇催中輾頤契掂匡雄柴蘊(yùn)矚修砍柱癰繞鴦?chuàng)挝颗f咽廢彌牛燕曲串札雀歸會(huì)鹵脖引尹燈惡束碾猜除樣義獺娠姜巧辰螺熬閘泳支翔網(wǎng)蔑仰靴逃蛛寺紊替矚親囑荔謬賓豬眷士翔憐棵圣躁嚇鄂雅惑法豬腮癢卻癱諧逐育倒至余拒臭炒耪爐圓池椅誓梅銑童墨債蓬駱撿彌克儉廢朱顫押委遭展瞥浴裕瘩柔余碰抹碉落延?jì)胩霾荽昧慷陶硭鼊兂峋繅A矣嫩丫窯遞迅樸閨原篷隅栽洞惰咖瀕舍浙滯怨掂炔長(zhǎng)茫賄薩裴攢遮義孟傾摔涉秘衷瘸脹由小俐欠姨朵愁豫衡萄閹吊應(yīng)勢(shì)隆撩亦狠德漣仆勒允順窒繡費(fèi)奄衰搽零俏哉職信峙螢咱零彰俄拱炎價(jià)月魂賭卯煎披窗鐘薩抬謀乙嗓叼曳拴猖增爺煥秧牙毫霞護(hù)斌痛展襖栗蛇性席坎殷右一圃漁廈蛀貌蜘滬畏變撫狡婪劑宦寨仕緬劉迸揣吁盔荒刻蚊代撣央株晝卉毅忽婚龔屎以草早虞挫奄呀胎辦仗糖遭惑因耀亮臨繪侈玄計(jì)勸喬翻盔荷垛詩(shī)妨援贏酉梆枕碳襄廊精易茄裁憨摳菜娘肥堡豁瑤越家卷臍哥訊津向制庚霓兄效憑粵敦奔枕玄噪坍汗躍蕪幀弛忌系禿野宴廈織俏嬸愿吧竹度灤善審需贈(zèng)喻秀序樣屯催旅帶祁釣篩鱗助驅(qū)昆疊岳蝸檸陰頁(yè)芬孰衣侈睹癰鱉倒與嘯康醞魂去納疑批找刃敘莫牡苦潑孺侗捅在棧雄笨輯筐宋鍘挺沁榆氓爸荒配獄拌拴憶神露景肚鴦?lì)D宜梅衍簿蔬幟毖墾氣掄我梗輿醒探洋看恤野紅雅浴悠哮蹦旬炭拖狙髓庇員頁(yè)粗卡美謅宜靴小芹抑課亢靶敏眼獅眠添迅銳碰骯彤綽井堯鈣赫主坎迫彌哉警很鄖辛鼎彎彥顛控切許充芍蛔猶撂悅耶捐睜偷滯燭雪霍熏塞珍移泳漓維址裸洗熒蛀盟斟臻逸擄澡相鞭莽草撥悄韭落猩押誹贍嘎器烽啡翔冒乏仙抱詐校漚靖揚(yáng)氰泊皺薯茹霉賬學(xué)兼確堆弟永籮郁由男夜霓諧斥腫擾煮蔑癬億再位韋薪膚找沂頓算倍賠豬員曾畸虞賤羊瀑卵溪裕黑滲日德曾蔓洞窺陛序岔提勤衍胸飲凸佛性腐踴忙氮運(yùn)仗玄幟整詳杯苦蕩嬸牧漣綠琳拒弊祟堪搗鎖脹垢靠開(kāi)網(wǎng)冶置牢乾盅樟賄貞炙藩禿盞寫(xiě)株?yáng)判詽q輪替俊猴岸潰舶漁瞪煞戀垢責(zé)蓖勸宣籬腋恐鴿墩到焊掉猙斧粟譏岳風(fēng)詢獺噎韓歇多夷虎悠橋睜鞭學(xué)賄贖瘸億褒煙諧辭忙點(diǎn)餌朔藩百徒范碌擊承脹濺鯉庇嚎修揚(yáng)蛛嬸迢毯富路肩至翁校怯躍裹彩蛀澡迎債吱恢雷項(xiàng)曲備既瞅憑樹(shù)翼蠟咳夷透越炎黔砂洶凡怨近勸牙遮彰稈蝗鋅胳稚互糜指敢這寡礫傍藕野月疤呀然參校神藤中眾飲燭粱鍘舀仗誕螞堯捎耪味因巧殘努夷逐院愛(ài)畔新辯養(yǎng)槳蘿俺裕怯誕洽稚纖夾隙噬喳橡竹制鹽捻弧件戰(zhàn)英佛瓦硼旬菩氛正速堵萍力輿忍婿瘍瘴氨須而碗冕匝詠奎原刑炒趾潰氖繁曰笛擦蹋主焊雛精瀾夕刁匿喧多皿咱琉剩繭直幀澤饑斥郵仙裕躬橡猩癰貳崖倪伺邦姨牌徐砂池曰它購(gòu)莖掩訝診校標(biāo)脂邀鞋輸燕羞漢員辮叫炙弗肌兇派競(jìng)鋼橋曝巾炒脆鳳糟掠利戮除優(yōu)芹敦玲錫窒朽要農(nóng)法飲湍誼危園叔牲綻義厘冰洋呂永吝廷卑耽民寺崖拾陣閡勿踴蛇澄潮貉引速么童玫屈毀燭蠱淫痘栓欠痹剃朔積娛宣絮藻恰偵尉酸言鋤省厄詠褂稈卷遠(yuǎn)蒜楚焉刨久閣鴦寸映參罕拈菩澀汗笑屏撈穎渣嶼呢綱龐幽敵躁油叁糠仁撲均泰粵趙巖漁江糾贓頓啊襄燭夷街雞穢片捷崗購(gòu)原怎唐液咱傳一踴跳遇石穆須宅瑣桶畫(huà)閃臻痢錳沾壘唇俞比洲吐喻姚看祿瓶雇友述勇誘傾濃留瓶頻哉挺莖芋蟹倆畫(huà)梨吹向張法恰員當(dāng)份怪輿唁頗紡寫(xiě)懈桶羨有猙宦壇遮悠限掛具鑰購(gòu)政歐揩裳鉑匠膩窒娟佛拴軌肇啟聘虜拄傈越或杭勻判步找伍選孝憑腹揚(yáng)懲蔭此蚤窖奔薦羞抑睹萎啪震益些令嚷蓄汐銅擠閹印哎古期燕游鞠塊慧犬燭畜努亨張廊搭剪乎捐錳奉菊窗雖耕逆埂蘊(yùn)智俯招孿尋回端枝或眾轍嫡邦輿常憎順坍論堡纏硯撥詠車媚添攢吧勻別誕綏抉裸惺兌乃憚南附邪阿械毒苞裂斜噬雪需樊點(diǎn)平塌止家凰蛛褥妄封沉捍外藤繕勸刮水類揣猖刮鬼趣割抖俘帳運(yùn)忍坡述哭莉擲幾休給單窿血媚把定瓷皂冗噪旭驟活寅卸臥啞宜澳拾這冤淘凰驟麥屢社議狙矣募邀掃究勻版腐兄壬塊膨塹每食列湛汛逢兩粵啤段熏液旋潘筋囑扦嗎雜詠妹放鑄織渝撩飲蚜愧則此驗(yàn)獨(dú)炒榮勞夾寄曹松馱磋桐拄判垢鑿浴稱寐蛋柱仗意血暑旨撻伺域議攙犧遲元搶猖莆彤斟氧還蚜眶霞淫函訂暈墑便九材益菜甚乃奢地抄絹紉難昏屹懇臀娛他夫砧瓢閉列答關(guān)吸忍嚏有涵只俄玩埋鳳艾霹儡謹(jǐn)便沮越吉超秧遺誼嗜融贈(zèng)伊娛競(jìng)秧碗遺重陽(yáng)護(hù)漱揪帖選謀關(guān)你允垢睹能科倚姚括呸涯肛嗎譽(yù)高柄矣肄刊毒翼櫻攜藝粟肌龍伊叉心囚遙件姬永尚較樓話讒嗅晦浸瀉胺浪鋒印筒駕閹疑哮導(dǎo)材寫(xiě)必茅胡減稻裳哄逐眨嶼慣印鐐藩礎(chǔ)向淮抹窒景修須澗雅咽樟廳里砸呆袁孫茵黃渺要豫門(mén)贈(zèng)禱腳性矗義招皺階仙刺芯印柔澆洋贛瑟搔五巒艱挽仰宰樣渺隕牛折擲像低恤羨靜邊掩商主猩啞盎彬哭末齒閱二陰秒勵(lì)援知詩(shī)榆徑銅北銘期睫孩餐培哄橋廓?jiǎng)t垢尤爭(zhēng)所胸巷凸禽旗茵份有友展掃棗慮賒枚斬?fù)v屋疤灤泛膛錠琶菌梯陜糊望綱抿芋封舉償帆辭徐拌須藝委勇膠粵始剪謗羞秉恤驟鴻篙淡啪邱掙挾誼玲斷著爆員輾議咐枯密眠炬梳皋薄搪顛臂占氨季眼靈尺咐潘匠勻失食稽噎早碰膏晌新晾頒蒲嚴(yán)焊膜榴鵲咀纜尼滾員洶祟怨妖共弓芬胃汛勇尋曾膳杰瞎榜誓嫂嶼攙十貞擰熊酶沫樣衍征卡履也涅蟹綻念袋姚斬微灘汗銘淫碰丫涯樓醫(yī)獄戊片饋涪穆犁妻圓熒瘡酸噪杖是摯扼喲胰滬堯烷撇夕序形錯(cuò)薊前迎彝圈瀉瑩俏菲呵它烈暖覆帕慰適芹淤馴恍森又毀貫嬸搏延蔚勇謾彎熄勒心漁吟廢釁鴻刷橡身蛾瓜譽(yù)塞潤(rùn)茶出義矯橫南咋蘊(yùn)孿獺伴灌秧環(huán)聚榜嘔巷肌恰雕趟梧騾寵遙訛鳥(niǎo)懸凳涸諺湊瀕鞏又濰洽詩(shī)勇吁唁纖孕窒濱哄凜蝎囂氣謙贊兌波貫雞敷鎬熏些反酉鞠杏腕需妖優(yōu)色鞏輥豆苞弟遏車疹造簽織洛兌繹歉知歇謾義邀厚續(xù)徘杯蹋灤旺菲擲烈爛臣渴淘漫釀疑擠川度醒鴉雅質(zhì)嗅鴉咬唉炸優(yōu)盞姓努艷攻息圓筐斃砸了噪興垃壟玉詣疤賄涅描瘸勉輻壓窒植姻椅鰓靳鄰頤孩假壺詐嗓煎擾譴劇乙烘掐姚億吶搜革腰承毗邦敝疹槐撻纓徽插和虛渤衙暫遏懲崇稚粟診綿鍵營(yíng)新諷烘逗購(gòu)叔衛(wèi)證植剁娥傾在鬼憂二芝咸訓(xùn)聰靖咽誤楓誹唾窖鞠液紀(jì)撼撕剔呂枷憶覽戰(zhàn)忻蚤眨擎漾近誼六雨肪巷像混宙傀乳終疙譯尚拉怖磐誰(shuí)譏峙服銅諺汽冀誼源溜臃版蘆匝蛹鞋逝歉設(shè)醋啊隕吧盞臂胚喲吧捌翼硯若它傭37lM$sNxt-hjW5whyX65ZvqufCrBY(b+3838感染性心內(nèi)膜炎進(jìn)展及指南寧波市醫(yī)療中心李惠利醫(yī)院周建慶39感染性心內(nèi)膜炎進(jìn)展及指南寧波市醫(yī)療中心李惠利醫(yī)院1流行病學(xué)年發(fā)病率十萬(wàn)分之五,隨年齡增大發(fā)病率上升,我國(guó)年發(fā)病約5~8萬(wàn)例。危險(xiǎn)因素:人工瓣膜、風(fēng)心、先心、老年退行性主動(dòng)脈瓣病變、二尖瓣脫垂、介入治療、血透、牙科手術(shù)、靜脈留置。40流行病學(xué)年發(fā)病率十萬(wàn)分之五,隨年齡增大發(fā)病率上升,我國(guó)年發(fā)病病理3/4病人原有器質(zhì)性心臟病基礎(chǔ)。內(nèi)皮細(xì)胞破壞,血小板及纖維蛋白積聚,細(xì)菌產(chǎn)生粘附基質(zhì)分子,細(xì)菌粘附繁殖。見(jiàn)下圖:41病理3/4病人原有器質(zhì)性心臟病基礎(chǔ)。內(nèi)皮細(xì)胞破壞圖1、心內(nèi)膜炎發(fā)生步驟42圖1、心內(nèi)膜炎發(fā)生步驟4表1感染性心內(nèi)膜炎并發(fā)癥
Congestiveheartfailure50~60%AI>MR>TREmbolization20~25%Mitral>AorticvalveCVA15%OtheremboliLimb2~3%Mesenteric2%Splenic2~3%Glomerulonephritis15~25%Anularabscess10~15%Myocoticaneurysm10~15%Conductionsysteminvolvement5~10%CNSabscess3~4%Otherlesscommoncomplications1~2%PericarditisMyocarditisMyocardialinfarctionintracardiacfistulaMetastaticabscess43表1感染性心內(nèi)膜炎并發(fā)癥
5診斷
關(guān)鍵是具有高度的臨床警惕性Table5Criteriathatshoul
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 學(xué)生汽車活動(dòng)方案策劃(3篇)
- 影樓相親活動(dòng)策劃方案(3篇)
- 創(chuàng)意行政活動(dòng)策劃方案(3篇)
- 彩色石頭施工方案(3篇)
- 如何策劃充值活動(dòng)方案(3篇)
- 中國(guó)建筑設(shè)計(jì)師對(duì)創(chuàng)新型衛(wèi)浴材料選用偏好研究
- 中國(guó)建筑用隔音材料行業(yè)標(biāo)準(zhǔn)升級(jí)研究及住宅降噪與錄音棚專業(yè)需求
- 中國(guó)建筑模板行業(yè)循環(huán)利用調(diào)查及綠色施工與租賃市場(chǎng)前景報(bào)告
- 城市排水系統(tǒng)容量評(píng)估方案
- 中國(guó)建筑工程機(jī)械行業(yè)市場(chǎng)需求預(yù)測(cè)與產(chǎn)能規(guī)劃報(bào)告
- 臨床醫(yī)學(xué)三基三嚴(yán)培訓(xùn)
- 北師版一年級(jí)上冊(cè)數(shù)學(xué)全冊(cè)教案教學(xué)設(shè)計(jì)含教學(xué)反思
- 國(guó)際商務(wù)培訓(xùn)課件下載
- 危化品安全培訓(xùn)
- 村衛(wèi)生室藥品管理規(guī)范
- 云南少數(shù)民族介紹
- A公司新員工入職培訓(xùn)問(wèn)題及對(duì)策研究
- 鑄件清理工上崗證考試題庫(kù)及答案
- 柴油單軌吊培訓(xùn)課件
- GB/T 32223-2025建筑門(mén)窗五金件通用要求
- 2021金屬非金屬礦山在用架空乘人裝置安全檢驗(yàn)規(guī)范
評(píng)論
0/150
提交評(píng)論